LaneLabs Product Claims Not in Contempt of FTC Consent Decree

NEWARK, N.J.A U.S. District Court judge ruled in favor of LaneLabs USA Inc., denying a contempt motion filed by FTC regarding advertising claims for two of the companys dietary supplement products. In his Aug. 11, 2009, ruling, Judge Dennis M. Cavanaugh ruled LaneLabs clearly offered support and substantiation for claims on AdvaCAL and Fertil Male.

FTC filed suit in January 2007, charging LaneLabs violated an earlier consent decree by making claims for AdvaCAL and Fertil Male without competent and reliable evidence. FTC and LaneLabs presented competing fact and expert testimony during a five-day hearing before Cavanaugh in April 2009. In the final ruling, Cavanaugh found FTC presented a nuanced case while LaneLabs provided credible medical testimony that the products in question are good products and could have the results advertised.

This was not a split decision victory for LaneLabs; it was a clean sweep said Andrew Lane, president of Waldwick, N.J.-based LaneLabs. I am heartened that a federal judge with no vested interestother than right and wrongagreed with us. AdvaCAL calcium simply works better; its an important product FTC wanted to quash and now cannot. This ruling is a big win for LaneLabs, other scientifically-advanced natural companies and the millions who trust specialty supplements.